Vanguard Group
ASMB icon

Vanguard Group’s Assembly Biosciences ASMB Stock Holding History

Vanguard Group’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$19.5M Buy
572,898
+70,786
+14% +$2.28M ﹤0.01% 2630
2025
Q3 		$12.9M Buy
502,112
+248,287
+98% +$5.45M ﹤0.01% 2839
2025
Q2 		$4.6M Buy
253,825
+37,842
+18% +$499K ﹤0.01% 3245
2025
Q1 		$2.06M Buy
215,983
+15,525
+8% +$203K ﹤0.01% 3482
2024
Q4 		$3.16M Hold
200,458
– – ﹤0.01% 3432
2024
Q3 		$3.03M Hold
200,458
– – ﹤0.01% 3435
2024
Q2 		$2.75M Buy
200,458
+4,090
+2% +$58.3K ﹤0.01% 3464
2024
Q1 		$2.61M Buy
196,368
+1,444
+0.7% +$16.8K ﹤0.01% 3509
2023
Q4 		$1.92M Buy
194,924
+8,258
+4% +$78.5K ﹤0.01% 3621
2023
Q3 		$1.98M Sell
186,666
-2,814
-1% -$33.9K ﹤0.01% 3579
2023
Q2 		$2.61M Hold
189,480
– – ﹤0.01% 3574
2023
Q1 		$1.91M Buy
189,480
+6,733
+4% +$114K ﹤0.01% 3692
2022
Q4 		$2.85M Sell
182,747
-819
-0.4% -$14K ﹤0.01% 3534
2022
Q3 		$3.61M Sell
183,566
-4,386
-2% -$106K ﹤0.01% 3491
2022
Q2 		$4.74M Buy
187,952
+52,259
+39% +$1.2M ﹤0.01% 3407
2022
Q1 		$3.35M Sell
135,693
-48,061
-26% -$1.03M ﹤0.01% 3721
2021
Q4 		$5.14M Buy
183,754
+25,110
+16% +$823K ﹤0.01% 3594
2021
Q3 		$6.63M Buy
158,644
+1,674
+1% +$70.2K ﹤0.01% 3488
2021
Q2 		$7.31M Sell
156,970
-10,228
-6% -$507K ﹤0.01% 3375
2021
Q1 		$9.23M Buy
167,198
+4,726
+3% +$313K ﹤0.01% 3191
2020
Q4 		$11.8M Buy
162,472
+30,421
+23% +$3.57M ﹤0.01% 2909
2020
Q3 		$26.1M Buy
132,051
+68
+0.1% +$17.1K ﹤0.01% 2328
2020
Q2 		$36.9M Buy
131,983
+8,116
+7% +$1.89M ﹤0.01% 2146
2020
Q1 		$22M Buy
123,867
+3,068
+3% +$658K ﹤0.01% 2239
2019
Q4 		$29.7M Buy
120,799
+23,813
+25% +$4.39M ﹤0.01% 2340
2019
Q3 		$11.4M Sell
96,986
-5,260
-5% -$796K ﹤0.01% 2744
2019
Q2 		$16.6M Buy
102,246
+12,204
+14% +$2.32M ﹤0.01% 2607
2019
Q1 		$21.3M Buy
90,042
+20,160
+29% +$5.1M ﹤0.01% 2481
2018
Q4 		$19M Sell
69,882
-17,739
-20% -$5.13M ﹤0.01% 2467
2018
Q3 		$39.1M Buy
87,621
+19,912
+29% +$9.33M ﹤0.01% 2266
2018
Q2 		$31.9M Buy
67,709
+1,688
+3% +$893K ﹤0.01% 2356
2018
Q1 		$38.9M Buy
66,021
+2,701
+4% +$1.67M ﹤0.01% 2200
2017
Q4 		$34.4M Buy
63,320
+8,234
+15% +$3.73M ﹤0.01% 2257
2017
Q3 		$23.1M Buy
55,086
+4,176
+8% +$1.28M ﹤0.01% 2425
2017
Q2 		$12.6M Buy
50,910
+8,922
+21% +$2.51M ﹤0.01% 2665
2017
Q1 		$12.8M Buy
41,988
+4,218
+11% +$1.03M ﹤0.01% 2643
2016
Q4 		$5.51M Buy
37,770
+1,572
+4% +$234K ﹤0.01% 3025
2016
Q3 		$3.13M Hold
36,198
– – ﹤0.01% 3217
2016
Q2 		$2.41M Sell
36,198
-3,063
-8% -$201K ﹤0.01% 3309
2016
Q1 		$2.37M Buy
39,261
+2,701
+7% +$181K ﹤0.01% 3313
2015
Q4 		$3.29M Buy
36,560
+1,906
+6% +$208K ﹤0.01% 3191
2015
Q3 		$3.98M Buy
34,654
+3,176
+10% +$559K ﹤0.01% 3075
2015
Q2 		$7.28M Buy
31,478
+5,277
+20% +$1.02M ﹤0.01% 2831
2015
Q1 		$4.16M Buy
26,201
+15,650
+148% +$2.12M ﹤0.01% 3083
2014
Q4 		$995K Buy
10,551
+1,101
+12% +$108K ﹤0.01% 3532
2014
Q3 		$929K Buy
9,450
+1,653
+21% +$147K ﹤0.01% 3529
2014
Q2 		$613K Buy
7,797
+1,160
+17% +$82.3K ﹤0.01% 3622
2014
Q1 		$510K Buy
6,637
+2,003
+43% +$312K ﹤0.01% 3651
2013
Q4 		$1.06M Buy
4,634
+1,364
+42% +$248K ﹤0.01% 3393
2013
Q3 		$567K Buy
3,270
+488
+18% +$74.8K ﹤0.01% 3517
2013
Q2 		$401K Buy
+2,782
New +$436K ﹤0.01% 3533

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group's ASMB Position: Q4 2025 in Review

Vanguard Group increased its Assembly Biosciences (ASMB) stake by 14% in Q4 2025, buying an estimated $2.28M and bringing the position to 572,898 shares worth $19.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2630.

Vanguard Group first reported a position in ASMB in Q2 2013 and has held it in 51 quarters since. The position peaked at $39.1M in Q3 2018. 69 funds tracked by Wall St. Rank hold ASMB as of Q4 2025.

  • Vanguard Group held 572,898 shares of Assembly Biosciences worth $19.5M as of Q4 2025.
  • Vanguard Group bought 70,786 Assembly Biosciences shares in Q4 2025, an estimated $2.28M.
  • Assembly Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2630 holding.
  • Vanguard Group first reported a position in Assembly Biosciences in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's Assembly Biosciences position peaked at $39.1M in Q3 2018.
  • 69 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.